These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Mutations in the organic cation/carnitine transporter OCTN2 in primary carnitine deficiency. Wang Y; Ye J; Ganapathy V; Longo N Proc Natl Acad Sci U S A; 1999 Mar; 96(5):2356-60. PubMed ID: 10051646 [TBL] [Abstract][Full Text] [Related]
44. Organic cation/carnitine transporter, OCTN2, is differentially expressed in the adult rat epididymis. Rodríguez CM; Labus JC; Hinton BT Biol Reprod; 2002 Jul; 67(1):314-9. PubMed ID: 12080034 [TBL] [Abstract][Full Text] [Related]
45. Embryonic lethality in mice due to carnitine transporter OCTN2 defect and placental carnitine deficiency. Shekhawat PS; Sonne S; Matern D; Ganapathy V Placenta; 2018 Sep; 69():71-73. PubMed ID: 30213487 [TBL] [Abstract][Full Text] [Related]
46. Carnitine deficiency in OCTN2-/- newborn mice leads to a severe gut and immune phenotype with widespread atrophy, apoptosis and a pro-inflammatory response. Sonne S; Shekhawat PS; Matern D; Ganapathy V; Ignatowicz L PLoS One; 2012; 7(10):e47729. PubMed ID: 23112839 [TBL] [Abstract][Full Text] [Related]
47. Glioma cells survival depends both on fatty acid oxidation and on functional carnitine transport by SLC22A5. Juraszek B; Czarnecka-Herok J; Nałęcz KA J Neurochem; 2021 Mar; 156(5):642-657. PubMed ID: 32654140 [TBL] [Abstract][Full Text] [Related]
48. Involvement of OCTN2 and B0,+ in the transport of carnitine through an in vitro model of the blood-brain barrier. Berezowski V; Miecz D; Marszałek M; Bröer A; Bröer S; Cecchelli R; Nałecz KA J Neurochem; 2004 Nov; 91(4):860-72. PubMed ID: 15525340 [TBL] [Abstract][Full Text] [Related]
49. Cotransporting Ion is a Trigger for Cellular Endocytosis of Transporter-Targeting Nanoparticles: A Case Study of High-Efficiency SLC22A5 (OCTN2)-Mediated Carnitine-Conjugated Nanoparticles for Oral Delivery of Therapeutic Drugs. Kou L; Yao Q; Sun M; Wu C; Wang J; Luo Q; Wang G; Du Y; Fu Q; Wang J; He Z; Ganapathy V; Sun J Adv Healthc Mater; 2017 Sep; 6(17):. PubMed ID: 28661032 [TBL] [Abstract][Full Text] [Related]
50. Carnitine transport: pathophysiology and metabolism of known molecular defects. Tein I J Inherit Metab Dis; 2003; 26(2-3):147-69. PubMed ID: 12889657 [TBL] [Abstract][Full Text] [Related]
51. Studies on functional sites of organic cation/carnitine transporter OCTN2 (SLC22A5) using a Ser467Cys mutant protein. Ohashi R; Tamai I; Inano A; Katsura M; Sai Y; Nezu J; Tsuji A J Pharmacol Exp Ther; 2002 Sep; 302(3):1286-94. PubMed ID: 12183691 [TBL] [Abstract][Full Text] [Related]
52. Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons. Jong NN; Nakanishi T; Liu JJ; Tamai I; McKeage MJ J Pharmacol Exp Ther; 2011 Aug; 338(2):537-47. PubMed ID: 21606177 [TBL] [Abstract][Full Text] [Related]
53. Muscle contraction increases carnitine uptake via translocation of OCTN2. Furuichi Y; Sugiura T; Kato Y; Takakura H; Hanai Y; Hashimoto T; Masuda K Biochem Biophys Res Commun; 2012 Feb; 418(4):774-9. PubMed ID: 22310714 [TBL] [Abstract][Full Text] [Related]
54. Functional and molecular studies in primary carnitine deficiency. Frigeni M; Balakrishnan B; Yin X; Calderon FRO; Mao R; Pasquali M; Longo N Hum Mutat; 2017 Dec; 38(12):1684-1699. PubMed ID: 28841266 [TBL] [Abstract][Full Text] [Related]
55. Functional genomics of OCTN2 variants informs protein-specific variant effect predictor for Carnitine Transporter Deficiency. Koleske ML; McInnes G; Brown JEH; Thomas N; Hutchinson K; Chin MY; Koehl A; Arkin MR; Schlessinger A; Gallagher RC; Song YS; Altman RB; Giacomini KM Proc Natl Acad Sci U S A; 2022 Nov; 119(46):e2210247119. PubMed ID: 36343260 [TBL] [Abstract][Full Text] [Related]
56. Protein phosphatase PP2A - a novel interacting partner of carnitine transporter OCTN2 (SLC22A5) in rat astrocytes. Juraszek B; Nałęcz KA J Neurochem; 2016 Nov; 139(4):537-551. PubMed ID: 27537937 [TBL] [Abstract][Full Text] [Related]
57. Pharmacological manipulation of L-carnitine transport into L6 cells with stable overexpression of human OCTN2. Todesco L; Bur D; Brooks H; Török M; Landmann L; Stieger B; Krähenbühl S Cell Mol Life Sci; 2008 May; 65(10):1596-608. PubMed ID: 18408886 [TBL] [Abstract][Full Text] [Related]
58. Hepatic uptake of gamma-butyrobetaine, a precursor of carnitine biosynthesis, in rats. Fujita M; Nakanishi T; Shibue Y; Kobayashi D; Moseley RH; Shirasaka Y; Tamai I Am J Physiol Gastrointest Liver Physiol; 2009 Oct; 297(4):G681-6. PubMed ID: 19679820 [TBL] [Abstract][Full Text] [Related]
59. Transport of butyryl-L-carnitine, a potential prodrug, via the carnitine transporter OCTN2 and the amino acid transporter ATB(0,+). Srinivas SR; Prasad PD; Umapathy NS; Ganapathy V; Shekhawat PS Am J Physiol Gastrointest Liver Physiol; 2007 Nov; 293(5):G1046-53. PubMed ID: 17855766 [TBL] [Abstract][Full Text] [Related]
60. Expression, localization, and function of the carnitine transporter octn2 (slc22a5) in human placenta. Grube M; Meyer Zu Schwabedissen H; Draber K; Präger D; Möritz KU; Linnemann K; Fusch C; Jedlitschky G; Kroemer HK Drug Metab Dispos; 2005 Jan; 33(1):31-7. PubMed ID: 15486076 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]